167 results about "Hepg2 cells" patented technology

The invention belongs to the technical field of specific fluorescent probe detection, and particularly relates to a near-infrared fluorescent probe for detecting hydrazine hydrate as well as a preparation method and application of the near-infrared fluorescent probe. The structural formula of the near-infrared fluorescent probe is # imgabs0. The invention provides a preparation method for synthesizing the probe by taking xanthene dye and acetyl chloride as raw materials. By researching the fluorescence spectrum of the fluorescent probe, the selectivity of the probe on N2H4 is evaluated, the fluorescence intensity of the probe is determined to be obviously enhanced only in the presence of N2H4, and the fluorescence intensity is positively correlated with the concentration of N2H4; meanwhile, the probe has the characteristics of quick response and near-infrared emission; the fluorescent probe disclosed by the invention has relatively small cytotoxicity and can be applied to detection of HepG2 cell exogenous hydrazine hydrate.

The invention belongs to the technical field of biological medicine, and particularly relates to an LYTAC molecule for targeted degradation of GPC3 and a preparation method and application of the LYTAC molecule. The LYTAC molecule is composed of a target TfR1 nucleic acid aptamer and a target GPC3 nucleic acid aptamer, wherein the nucleotide sequence of the targeted TfR1 nucleic acid aptamer is as shown in SEQ ID NO: 1; the nucleotide sequence of the targeted GPC3 nucleic acid aptamer is as shown in SEQ ID NO: 2. According to the present invention, the research results show that the GPC3 protein content is not affected by the single TfR1 nucleic acid aptamer or the GPC3 nucleic acid aptamer, and the LYTAC molecule can significantly reduce the GPC3 protein content on the surfaces of Hep3B and HepG2 cells. The LYTAC molecule induces GPC3 protein degradation through a lysosome way, then proliferation and migration of liver cancer cells are inhibited, liver cancer treatment is achieved, and the LYTAC molecule has wide application prospects.

The invention aims to provide a chlorella pyrenoidosa peptide with an effect of preventing alcoholic liver injury, which is prepared by the following steps: crushing chlorella pyrenoidosa, mixing with water, freezing and thawing, and performing ultrasonic treatment to prepare homogenate; alkaline protease is added for enzymolysis, and then flavourzyme is added for enzymolysis; and after the enzymolysis product is adsorbed by activated carbon, the supernate is adsorbed by using an SP Sephadex C25 cation exchange medium. The amino acid sequence of the chlorella pyrenoidosa peptide is PSEQ ID NO: 1-5. The chlorella pyrenoidosa peptide provided by the invention is obtained by enzymolysis, adsorption and cation exchange chromatography technologies, and is verified by a HepG2 cell model to obviously relieve alcoholic liver injury. The raw materials are natural and safe, the process is accurate and efficient, and industrialization potential is achieved. Meanwhile, the peptide is suitable for development of functional food, health care products and medicines, and a low-toxicity and sustainable liver protection solution is provided.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention relates to a 5, 9-di-tert-butyl naphtho-indolizine phenothiazine compound as well as a preparation method and medical application thereof. The compound is efficiently synthesized through Ullmann coupling and palladium-catalyzed intramolecular arylation reaction. In-vitro anti-tumor activity research shows that the compound has remarkable selective inhibitory activity on various human tumor cell lines, and particularly, the inhibitory effect on non-small cell lung cancer A549 cells (IC50 = 0.21 mu M) is improved by two orders of magnitude compared with that of cis-platinum; iC50 (half maximal inhibitory concentration) of other cell lines are as follows: 1.26 mu M of prostate cancer PC-3 cells, 6.78 mu M of liver cancer HepG2 cells, 7.99 mu M of cervical cancer Hela cells and 25.46 mu M of breast cancer MCF-7 cells. Preliminary toxicity experiments prove that the compound has the characteristic of low cytotoxicity. The compound can be used as a novel high-efficiency low-toxicity anti-tumor lead compound, and provides an important structural basis for the development of anti-cancer drugs.

The present invention discloses a polyporus badius polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction. The polyporus badius polysaccharide (PPP-0A) includes galactose, fucose, glucose, mannose and xylose, and the molar ratios are 62.26%, 16.96%, 15.23%, 4.68% and 0.87% respectively. The present invention uses techniques such as methylation, scanning electron microscopy, thermogravimetric analysis, nuclear magnetic resonance and atomic force microscopy to determine the structural characteristics of PPP-0A, analyze its composition and properties, and its inhibitory effects on the activities of α-glucosidase and α-amylase. In addition, an in vitro HepG2 cell model induced by high blood glucose and high insulin levels was used to study the hypoglycemic effect of PPP-0A. The present invention provides a theoretical basis for clarifying the relationship between the hypoglycemic activity of PPP-0A and its hypoglycemic effect on type 2 diabetic mice.

The invention discloses novel application of ganoderic acid B, belongs to the field of liver injury treatment, and particularly relates to application of ganoderic acid B in preparation of a medicine for treating liver cell injury caused by aflatoxin. According to the invention, human liver cancer HepG2 cells are utilized to construct an AFB1 cell injury model, lucid ganoderma active ingredients with a protection effect on injury are screened out, and the resistance mechanism of the lucid ganoderma active ingredients is researched and predicted, so that a new method and a new target spot are provided for searching for diseases caused by AFB1 prevention and treatment. A new method can be provided for preventing and treating the liver cancer caused by the AFB1.

The research finds that the SUMOylation level of the liver in a clinical specimen and an animal model of the metabolic dysfunction fatty liver disease is obviously reduced. UBC9 is used as the only key E2 ligase for SUMOylation to regulate and control the SUMOylation level. The invention discloses application of a UBC9 gene overexpression preparation in drugs for treating or preventing metabolic dysfunction fatty liver diseases. Through overexpression of liver specificity UBC9 mediated by an AAV adeno-associated virus vector or overexpression of UBC9 in HepG2 cells by a lentiviral vector, lipid deposition of a C57 mouse liver induced by high fat diet and a cell model treated by palmitate can be remarkably improved, and reduction of the SUMOylation level of the mouse liver and the human HepG2 cells under the high fat background can be reversed. Therefore, the UBC9 gene overexpression preparation can be used for developing drugs for treating metabolic dysfunction fatty liver diseases.

The application provides a benzyl chromone compound and a preparation method and application thereof. The application takes dry fruit bodies of Leucangium alectorium as raw materials, carries out ethanol extraction, ethyl acetate extraction, then carries out rough separation on the ethyl acetate phase obtained by extraction with different proportions of dichloromethane-methanol solution, and then carries out elution separation with different proportions of methanol-water to obtain a novel structure benzyl chromone compound. The benzyl chromone compound provided by the application has significant in-vitro inhibition activity on HepG2 cell proliferation, and when the treatment concentration is below 160 muM, the inhibition activity on liver cancer cells is obviously better than that of cisplatin, and the benzyl chromone compound can be used for preparing drugs for treating and preventing liver cancer. Meanwhile, the raw material of the compound is rich in source, low in price, simple in preparation process and convenient for industrial application, so the discovery of the compound is expected to provide a promising treatment scheme for liver cancer patients, and has great significance for breaking through the bottleneck of liver cancer treatment.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

The application belongs to the technical field of medicine preparation, and particularly relates to a magnetic layered double hydroxide, a targeted drug-loaded nano preparation, a preparation method and application of a tumor-targeted drug-loaded nano preparation. The preparation method of the magnetic layered double hydroxide provided by the application can prepare Fe3O4 nanoparticles with small particle size, and further prepare the magnetic layered double hydroxide which can be used as a water-soluble drug carrier. The magnetic layered double hydroxide is used for preparing the targeted drug-loaded nano preparation and the tumor-targeted drug-loaded nano preparation, and can be used for delivering water-soluble drugs such as 5-fluorouracil. The tumor-targeted drug-loaded nano preparation has good dispersity and can be actively targeted to HepG2 cells with high FR expression, has a good inhibitory effect on liver cancer cells, and is expected to provide a potential new treatment system for magnetic chemotherapy.

The invention relates to phloroglucinol meroterpenoid compounds Hypercm A and B and a preparation method and application thereof, and belongs to the field of medical chemistry, the phloroglucinol meroterpenoid compounds Hypercm A and B are extracted and separated from Hypericum acalyx branches and leaves for the first time, and the structural formulas of the phloroglucinol meroterpenoid compounds Hypercm A and B are formula (I) and formula (II). The phloroglucinol meroterpenoids Hypericmoses A and B and pharmaceutically acceptable auxiliary materials have the advantages that the phloroglucinol meroterpenoids Hypericmoses A and B have obvious inhibition effects on HepG2 cells induced by oleic acid (OA) and have application potential in the field of lipid-lowering medicines, and the invention further relates to a pharmaceutical composition which comprises the phloroglucinol meroterpenoids Hypericmoses A and B and pharmaceutically acceptable auxiliary materials and has lipid-lowering effects.

The present invention discloses an application of a medicated serum prepared from Herba Lycopodii in liver cancer cells, and belongs to the field of medical technology. The present invention provides a medicated serum prepared from Herba Lycopodii in the preparation of a drug for inhibiting the proliferation and invasion of liver cancer cells, and promoting apoptosis of liver cancer cells. The present invention verifies that the Herba Lycopodii medicated serum can effectively inhibit the proliferation and invasion of HepG2 cells, promote cell apoptosis, and inhibit the phosphorylation of mTOR protein in the mTOR signaling pathway of HepG2 cells, upregulate the expression of pro-apoptotic proteins caspase-9, caspase-3, and bax, and downregulate the expression of anti-apoptotic protein bcl-2. The present invention studies the effects of the Herba Lycopodii medicated serum on related apoptosis genes in the mTOR molecular signaling pathway of HepG2 liver cancer cells and the proliferation, invasion, and apoptosis of HepG2 liver cancer cells from the perspective of in vitro experiments, in order to provide an experimental basis for clinical application.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

This invention discloses a eucalyptane-type sesquiterpene dimer compound, its preparation method, and its applications, belonging to the field of pharmaceutical preparation technology. The six eucalyptane-type sesquiterpene dimers (compounds 1-6) disclosed in this invention are novel compounds with defined stereostructures and optically pure composition, exhibiting varying degrees of cytotoxic activity against HepG2, Hep3B, and Huh7 cells. Using sorafenib as a positive control, compounds 1, 5, and 6 showed stronger cytotoxic activity against HepG2 cells than the positive control sorafenib, compound 5 exhibited the strongest cytotoxic activity against Hep3B cells, and compounds 1, 4, 5, and 6 showed stronger cytotoxic activity against Huh7 cells than the positive control sorafenib. Therefore, compounds 1-6 disclosed in this invention have the potential to be developed into anti-hepatocellular carcinoma drugs, showing promising application prospects, and also provide important theoretical support for the further development of Atractylodes macrocephala medicinal plant resources.

The invention provides an application of a rhododendron dauricum extract in treating fatty liver diseases related to metabolic dysfunction. The folium rhododendri daurici extract is obtained by ultrasonic extraction of folium rhododendri daurici powder with an 80% ethanol solution as a solvent and is used for treating a hepatocyte lipid accumulation model and a metabolic dysfunction fatty liver disease mouse model. Experimental results show that the folium rhododendri daurici extract can inhibit lipid accumulation in HepG2 cells, relieve liver lipid accumulation of mice with metabolic dysfunction and fatty liver diseases, reduce TC, TG, AST and ALT levels of serum, reduce MDA expression in the serum, increase GSH expression in liver tissues, relieve liver injury and improve the antioxidant capacity of the mice. Therefore, the folium rhododendri daurici extract has a definite effect in the aspect of treating the metabolic dysfunction fatty liver disease, is simple in extraction process and small in toxic and side effects, and has a wide application prospect.

The invention belongs to the technical field of biology, and discloses application of DVM nanoparticles in preparation of products for treating and / or preventing alcoholic liver diseases, the DVM nanoparticles contain gallic acid derivatives VM and dihydromyricetin; the mass ratio of the gallic acid derivative VM to the dihydromyricetin is 1: 3; in alcohol-induced HepG2 cells, the DVM nanoparticles can better reduce apoptosis of hepatocytes and generation of ROS, improve ADH activity, reduce AST and ALT activities in the cells and improve the hangover alleviating ability in mice, and have a more excellent liver protection effect compared with gallic acid and a positive drug silibinin.

The method comprises the following steps: amplifying SIRT3 and SIRT4 genes from human, cloning the SIRT3 and SIRT4 genes to a plasmid vector to construct a pSIRT3-4 plasmid, and mediating the simultaneous expression of the two genes by using an internal ribosome entry site (IRES). According to the present invention, the insulin resistance (IR) model of the HepG2 cell is established by using the 35mM high glucose solution, and after the transfection of the pSIRT3-4 plasmid, the uptake of glucose is improved, the conduction of the insulin signal is recovered, the sensitivity of the HepG2 cell to the insulin is improved, the IR is improved, and the dysfunction of the mitochondria is recovered. The pSIRT3-4 plasmid is wrapped by insulin-coupled cationic liposome and is applied to an IR mouse model, and research proves that lipid accumulation in the IR mouse liver is obviously reduced, and the mitochondrial function of the IR mouse liver is obviously improved. The pSIRT3-4 plasmid constructed by the invention provides a new gene therapy means for the treatment of insulin resistance.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and particularly relates to a synthesis method of a novel polycyclic aromatic hydrocarbon derivate 2, 6-di-tert-butyl pyrene and indolizine phenothiazine compound and application of the compound in the aspect of anti-cancer drugs. The synthesis process is simple and convenient, conditions are mild, and the yield is ideal. Pharmacodynamic evaluation shows that the compound shows strong inhibitory activity on various human cancer cell lines, and the IC50 values are respectively cervical cancer Hela cells (0.17 mu M), lung cancer A549 cells (0.3 mu M), prostatic cancer PC-3 cells (0.42 mu M) and liver cancer HepG2 cells (10.79 mu M), which are respectively reduced by 109 times, 173 times, 35 times and 1.8 times compared with positive control drug cis-platinum. In addition to efficiently inhibiting cancer cells, the compound has low toxicity to normal cells, meets the basic requirements of excellent anti-cancer drugs, and shows important application value and potential in the field of research and development of novel anti-cancer drugs.

The present invention discloses a lipid droplet-targeted bifunctional ratiometric fluorescent probe and its application in the preparation of a •OH detection reagent, wherein the structure of the bifunctional ratiometric fluorescent probe is as follows: #imgabs0#. The bifunctional ratiometric fluorescent probe of the present invention can respond to different concentrations of •OH with ratiometric fluorescence, with a detection limit as low as 1.18nM and a difference between the two emission peaks as high as 140 nm, enabling dual-channel detection without crosstalk. Cytotoxicity tests have shown that the probe has good biocompatibility, and confocal fluorescence microscopy experiments have shown that the probe has good photostability for HepG2 cells, has the ability to monitor changes in endogenous and exogenous •OH concentrations in cells through dual channels, and has the ability to image lipid droplets (R 2 =0.85), which is suitable for confocal fluorescence imaging of intracellular lipid droplet tracking.

The invention discloses an extraction and purification method and application of malus toringoides leaf and leaf tea polyphenol, and belongs to the field of separation and application of natural plant products. The method comprises the following steps: mixing malus toringoides fruit and leaf dry tea powder with ethanol according to a set material-to-liquid ratio, and carrying out ultrasonic treatment on the mixed solution to obtain a malus toringoides fruit and leaf tea polyphenol crude extract; adding the malus toringoides leaf and leaf polyphenol crude extract into a chromatographic column filled with macroporous resin, and performing elution adsorption with an ethanol solution after adsorption equilibrium is achieved; and recovering the eluent, and freeze-drying to obtain the purified malus toringoides leaf and leaf tea polyphenol extract. The malus toringoides leaf and leaf tea polyphenol extract obtained by the invention has strong free radical scavenging capacity, can effectively inhibit active oxygen of HepG2 cells, and can be used for researching, developing and preparing antioxidant functional foods and medicines.

The application discloses a Salicornia polysaccharide as well as a preparation method and application thereof. The Salicornia polysaccharide is composed of 11 kinds of monosaccharides, wherein arabinose (24.96%), galactose (30.39%) and galacturonic acid (23.20%) are main monosaccharides of the polysaccharide, and the relative molecular weight is 3.24*10 4 Da. The Salicornia polysaccharide has a very special surface morphological structure, and presents a regular sawtooth distribution. The anti-tumor activity of the Salicornia polysaccharide is researched, and it is found that the polysaccharide can inhibit the growth of HepG2 cells, and the molecular mechanism of the anti-tumor activity is that the polysaccharide can induce the apoptosis of HepG2 cells. The Salicornia polysaccharide has significant anti-tumor activity, can be used as a candidate drug for developing an anti-tumor drug, and has a wide development prospect.

The present invention belongs to the technical field of polysaccharide extraction. More specifically, it relates to the extraction and application of Liubao tea polysaccharide with in vitro antioxidant activity, blood glucose-lowering and blood lipid-lowering activities. The present invention obtained the Liubao tea polysaccharide component TPS-5 by extraction with water extraction and alcohol precipitation methods, purification with DEAE-52 cellulose column and Sephadex G-200 gel column, and identified and analyzed its structure. In vitro biological activities confirmed that TPS-5 has antioxidant, bile salt-binding, α-amylase and α-glucosidase inhibitory activities. HepG2 cell experiments proved that TPS-5 has good effects on lowering blood glucose, blood lipid and cholesterol. These results indicate that TPS-5 can be used as a natural antioxidant resource to regulate blood lipid and blood glucose, and may also be used as a natural ingredient for treating diabetes. The present invention lays a theoretical foundation for the application of functional active Liubao tea polysaccharide in health foods or functional foods.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The invention belongs to the field of functional food and biomedicine, and relates to a method for preparing polysaccharide modified selenium nanoparticles. A chitosan oligosaccharide-sodium alginate compound is used as a stabilizer, Na2SeO3 is used as a selenium source, Vc is used as a reducing agent, novel selenium nano-particles (COS-SA-SeNPs) are prepared through a chemical synthesis method, the stability of the particles is improved, and the optimal preparation method is determined by taking the particle size as an index. Investigating the physical and chemical stability; the interaction mode of the COS-SA-SeNPs is defined; the influence of the COS-SA-SeNPs on HepG2 cell growth is further researched, and an action mechanism of inducing HepG2 cell ferroptosis by the COS-SA-SeNPs is disclosed. According to the invention, the stability of SeNPs is improved by preparing COS-SA-SeNPs, the anti-hepatoma activity of the SeNPs is proved, and reference is provided for further development and utilization of the SeNPs in the fields of functional foods with anti-hepatoma effects, foods for special medicine, foods for special diets and the like.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The application discloses a white tea composition and an extraction process and application thereof, and the composition is prepared from white tea, roxburgh rose, honeysuckle, mulberry and ginkgo leaves, wherein the white tea, roxburgh rose and honeysuckle are each 5-15 parts, and the ginkgo leaves are 2-8 parts; the extraction process is that the five medicinal materials are weighed according to the proportion, 45%-75% ethanol is added, microwave-assisted extraction is adopted, and the extract is collected, and the white tea composition can significantly inhibit H2O2-induced HepG2 cell oxidative damage, restore cell viability, effectively reduce intracellular ROS level, improve mitochondrial membrane potential, significantly enhance endogenous antioxidant enzyme activities such as SOD, GPX and GSH, and reduce the content of MDA, thereby providing theoretical support for application research and product development of the composition in the fields of health food, medicine and cosmetics, and embodying good application potential of the natural antioxidant. The optimized composition extraction process is stable and feasible, and the comprehensive antioxidant effect of the extract under the condition is significant.

The invention discloses a polypeptide with antioxidant activity and application thereof, and belongs to the technical field of biological medicine and fine chemical engineering. The amino acid sequence of the polypeptide is selected from QY, YG, YYYY, QPYY or WHYHDYKY. HPLC and MS structure confirmation shows that the synthesized polypeptide is high in purity and accurate in structure. In-vitro chemical experiments prove that the polypeptide (especially WHYHDYKY) has extremely high ABTS and DPPH free radical scavenging capacity, and the activity of the polypeptide is superior to or equal to that of glutathione (GSH). Cell experiments show that part of polypeptides (such as QY, YG, YYYY and QPYY) can significantly improve the survival rate of HepG2 cells under an oxidative damage model, and have a significant cell protection function. The polypeptide can be applied to the fields of antioxidant drugs, functional food, cosmetics, industrial antioxidants and the like according to the characteristics of the polypeptide.

The application relates to the technical field of drug delivery, in particular to a ZIF-8 / PDA composite material and a preparation method and application thereof. The ZIF-8 / PDA composite material provided by the application has good feasibility in terms of loading and delivering curcumin. The ZIF-8 material is modified by polydopamine, and the loading effect of the ZIF-8 material as a carrier on drugs is improved. The characterization results show that the drug loading performance of ZIF-8@PDA is obviously improved. The in-vitro release experiment results show that CuR@ZIF-8@PDA has more significant pH response drug release characteristics, shows good inhibition on Staphylococcus aureus and Escherichia coli, the hemolysis rate is 3.1%, is within a safe range, the inhibition on HepG2 cells is stronger than that of CuR@ZIF-8, and more obvious oxidative stress reaction and cell apoptosis can be induced.